What is forming beneath today's signals is a structural reorganization of the psychedelic development stack. For the past three years, the field operated on a loosely parallel model — ibogaine, MDMA, and psilocybin advancing roughly simultaneously toward different regulatory finish lines. That model is now visibly stratifying. Ibogaine is being channeled into a supervised hospital-access framework that is neither full approval nor continued prohibition — a cardiac-monitoring prerequisite pathway that will likely codify into legislative language before 2027, and that effectively delays rescheduling through 2028 while preserving legitimate clinical access for the highest-need populations. MDMA's resubmission timeline remains blocked by data integrity concerns that are structural, not procedural. This leaves psilocybin — with the cleanest safety profile and the most advanced Phase 3 infrastructure — as the compound most likely to reach an FDA advisory committee by Q2 2027. The cocaine RCT finding, paradoxically, strengthens psilocybin's near-term regulatory position: it is anomalous and mechanistically important, but it does not impair the depression indication, and it opens a productive new sub-literature on consolidation versus extinction that will attract NIH and DARPA funding for years. The highest trajectory visible from here is not a single compound winning — it is a field maturing enough to tolerate complexity: ibogaine moving toward analog development and hospital access simultaneously, psilocybin advancing its NDA while the mechanistic literature deepens, and $50M or more in federal grants flowing toward neuroplasticity research that could eventually yield safer molecules than any currently in clinical development.
For veterans living with treatment-resistant PTSD and the families who have watched them exhaust every approved option, today's news lands with particular weight. The cardiac monitoring requirement is not a betrayal — most of these men and women would accept a hospital bed and an EKG lead if it meant legitimate, supervised access to a compound that has shown genuine promise where nothing else has. What is genuinely possible from here is a pathway that takes their lives seriously enough to build the safety infrastructure around the medicine, rather than refusing the medicine because the infrastructure doesn't yet exist. That is the more difficult, more honest, more humane version of yes — and the signals today suggest it is the version that is actually forming.
OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward.
The future does not wait for permission — it arrives through those who are ready.
72%
Ibogaine stays illegal Schedule I drug through 2028
Ibogaine will remain a Schedule I controlled substance (the strictest category, meaning no approved medical use) through 2028 because the US government almost never moves drugs down from Schedule I. Even if someone files a formal petition asking the DEA (the US drug enforcement agency) to reconsider, the DEA will likely reject it or sit on it without action.
→ Ibogaine will almost certainly stay as an illegal Schedule I drug through 2028 because the US government rarely moves drugs to less restricted categories.
Resolves: 2028-12-31 · USA
REGULATION
the precise call ▾
Ibogaine remains Schedule I through 2028 with no rescheduling petition advancing past initial DEA review. Base rate for Schedule I rescheduling is extremely low; no substance has been rescheduled downward from Schedule I through the standard DEA petition process in decades without prior FDA scheduling recommendation. Cardiac safety data provides additional public health justification for DEA to defer. T
41%
FDA publishes cardiac monitoring rules for ibogaine trials by end of 2026
The FDA (the US drug regulator) will likely publish formal written guidance saying that anyone running clinical trials with ibogaine must have hospital-grade heart monitoring equipment. This matters because ibogaine can cause dangerous heart rhythm problems, and the FDA needs to document the safety rules before more people can test it.
→ The FDA will almost certainly require hospital-grade heart monitoring for any ibogaine trials or approved use because the heart risks are now well-documented.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
FDA publishes formal guidance requiring cardiac monitoring infrastructure as prerequisite for ibogaine IND expansion or rescheduling petition before end of 2026. Multiple published cardiac safety papers on ibogaine QT prolongation and ventricular arrhythmia constitute a formal pharmacovigilance safety signal. FDA has procedural obligations under 21 CFR to respond to documented safety signals affecting IND expansions. However, formal guidance documents (not j
7%
Federal ibogaine cardiac monitoring rules written into law by August 2026
Congress or a federal agency will write ibogaine heart-monitoring requirements into actual legal language by mid-August 2026. This is much less likely than FDA guidance alone because Congress moves slowly and there's no emergency forcing the issue.
→ Federal laws specifically codifying ibogaine cardiac monitoring requirements by August 2026 are very unlikely; FDA guidance is far more probable.
Resolves: 2026-08-13 · USA
REGULATION
the precise call ▾
Formal federal regulatory or legislative language codifying hospital-grade cardiac monitoring as a prerequisite for any ibogaine access pathway is published before 2026-08-13. The resolve date of August 13, 2026 is only ~3 months away. Legislative language requires bill introduction, committee markup, and passage; regulatory language requires notice-and-comment or at minimum formal agency publication. Neither process moves this fast absent a declared public health emergen
62%
Psilocybin-cocaine study sparks 10+ papers on brain mechanisms within 2 years
A clinical trial combining psilocybin with cocaine addiction treatment will show an unusual result: people's brains learn to stop craving cocaine, but they also don't relapse the way brain science predicts. This contradiction will be so interesting that scientists will publish at least 10 peer-reviewed papers in the next two years trying to explain which parts of the brain are really responsible.
→ A surprising finding in psilocybin-cocaine trials will probably spark at least 10 scientific papers trying to explain the unexpected brain mechanisms.
Resolves: 2028-05-15 · Global
RESEARCH
the precise call ▾
The dissociation between extinction and relapse-prevention in the cocaine psilocybin RCT becomes a primary mechanistic research focus, generating an identifiable sub-literature of at least 10 peer-reviewed papers on consolidation vs. extinction within 24 months of publication. Sharpened to a falsifiable threshold of 10 peer-reviewed papers. The finding is genuinely anomalous: behavioral extinction without relapse prevention implies separate neural substrates (likely prelimbic vs. infralimbic PFC pathways, or BDNF-mediated reconsolidation vs. extinction circuits). This is
38%
US government funds $50M+ ibogaine research and plasticity studies by late 2027
The US government—through the NIH (National Institutes of Health) or DARPA (the Defense Department's research agency)—will announce at least $50 million in new research grants for ibogaine and brain plasticity studies by late 2027. This matters because government funding signals that ibogaine is moving from fringe to mainstream science, and the money enables labs to do expensive mechanistic research.
→ There's a moderate chance the US government will announce $50+ million in ibogaine and brain plasticity research funding by late 2027.
Resolves: 2027-11-15 · USA
RESEARCH
the precise call ▾
At least $50M in new NIH and DARPA grant awards targeting ibogaine analog development and neuroplasticity mechanism characterization is announced within 18 months of 2026-05-15. Juvenile-like plasticity restoration (BDNF/TrkB signaling, perineuronal net remodeling) is a credible and high-value finding with dual-use applications for TBI and cognitive restoration. DARPA has funded analogous plasticity research. NIH HEAL has existing ibogaine infrastructure grants. However, $5